Wells Fargo & Company started coverage on shares of Envista (NYSE:NVST – Free Report) in a research note issued to investors on Tuesday morning, MarketBeat reports. The firm issued an equal weight rating and a $20.00 target price on the stock.
NVST has been the subject of a number of other research reports. Stifel Nicolaus lowered their price target on Envista from $20.00 to $18.00 and set a buy rating on the stock in a report on Tuesday, July 30th. Evercore ISI raised their target price on shares of Envista from $18.00 to $23.00 and gave the company an outperform rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. lowered shares of Envista from an overweight rating to a neutral rating and cut their target price for the stock from $23.00 to $16.00 in a research report on Thursday, August 8th. Piper Sandler lowered their price target on Envista from $18.00 to $16.00 and set a neutral rating on the stock in a research report on Tuesday, July 30th. Finally, Robert W. Baird cut their price objective on Envista from $19.00 to $17.00 and set a neutral rating for the company in a research report on Monday, July 22nd. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Hold and a consensus price target of $19.63.
Read Our Latest Stock Report on NVST
Envista Stock Performance
Envista (NYSE:NVST – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.16). The company had revenue of $633.10 million for the quarter, compared to the consensus estimate of $646.88 million. Envista had a negative net margin of 52.25% and a positive return on equity of 4.86%. Envista’s quarterly revenue was down 4.4% on a year-over-year basis. During the same quarter last year, the business earned $0.43 earnings per share. On average, equities research analysts expect that Envista will post 0.69 EPS for the current fiscal year.
Insider Activity
In other news, CFO Eric D. Hammes bought 24,532 shares of Envista stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $16.33 per share, with a total value of $400,607.56. Following the completion of the transaction, the chief financial officer now directly owns 24,532 shares in the company, valued at $400,607.56. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in shares of Envista by 69.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares in the last quarter. Versant Capital Management Inc raised its stake in Envista by 1,420.3% during the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after acquiring an additional 2,940 shares in the last quarter. Innealta Capital LLC acquired a new position in Envista during the second quarter worth $78,000. Summit Securities Group LLC bought a new position in shares of Envista during the second quarter valued at $85,000. Finally, Signaturefd LLC boosted its stake in shares of Envista by 85.9% in the 2nd quarter. Signaturefd LLC now owns 5,345 shares of the company’s stock valued at $89,000 after purchasing an additional 2,470 shares in the last quarter.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories
- Five stocks we like better than Envista
- Dividend Payout Ratio Calculator
- AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- AZZ Stock Gains Momentum: Analysts Forecast 25% Upside From Here
- Airline Stocks – Top Airline Stocks to Buy Now
- Volatility in Applied Digital May Create an Entry Opportunity
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.